RxDoctor Payments Data

Lori Long

Family · Lawrenceburg, TNNPI 1912270265

Payments from drug & device makers

$980in general payments, 2019–2025

Across 51 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$190
  • AbbVie$151
  • Novo Nordisk$105
  • Boehringer Ingelheim$104
  • Xeris Pharmaceuticals, Inc.$77
  • Lilly USA, LLC$77
  • plus $276 from 8 others

What the payments were for

  • Food & beverage$93595%
  • Education$455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$980 in reported general payments places this provider in the 60th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$11,169
Medicare patients
149
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$117,505
FarxigaDapagliflozin Propanediol66$54,228
TrulicityDulaglutide44$54,112
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$41,657
XareltoRivaroxaban54$34,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$32,904
JardianceEmpagliflozin29$24,503
EliquisApixaban31$22,272
JanuviaSitagliptin Phosphate29$20,794
UbrelvyUbrogepant13$19,777
RybelsusSemaglutide15$18,233
LinzessLinaclotide26$17,976
TradjentaLinagliptin12$7,564
InvokanaCanagliflozin12$6,352
Synjardy XrEmpagliflozin/Metformin Hcl11$5,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$105$135,73796 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$190$100,573118 claims
Lilly USA, LLCTrulicity$77$54,11244 claims
AbbVieUbrelvy, Linzess, Synthroid$151$38,94062 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$104$37,65052 claims
PfizerEliquis$37$22,27231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,706 family providers in Tennessee.

Other family in Lawrenceburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →